DK0720483T3 - Anvendelse af væksthormon ved fremstilling af et medikament til behandling af iskæmisk hjerneödelæggelse og demens - Google Patents
Anvendelse af væksthormon ved fremstilling af et medikament til behandling af iskæmisk hjerneödelæggelse og demensInfo
- Publication number
- DK0720483T3 DK0720483T3 DK94928538T DK94928538T DK0720483T3 DK 0720483 T3 DK0720483 T3 DK 0720483T3 DK 94928538 T DK94928538 T DK 94928538T DK 94928538 T DK94928538 T DK 94928538T DK 0720483 T3 DK0720483 T3 DK 0720483T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- growth hormone
- dementia
- medicament
- manufacture
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 3
- 108010051696 Growth Hormone Proteins 0.000 title abstract 3
- 239000000122 growth hormone Substances 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title 1
- 230000006931 brain damage Effects 0.000 title 1
- 231100000874 brain damage Toxicity 0.000 title 1
- 208000029028 brain injury Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000000302 ischemic effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 abstract 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 abstract 1
- 102000013275 Somatomedins Human genes 0.000 abstract 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9303068A SE9303068D0 (sv) | 1993-09-21 | 1993-09-21 | New use |
| PCT/SE1994/000875 WO1995008345A1 (en) | 1993-09-21 | 1994-09-21 | Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0720483T3 true DK0720483T3 (da) | 2004-08-09 |
Family
ID=20391162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94928538T DK0720483T3 (da) | 1993-09-21 | 1994-09-21 | Anvendelse af væksthormon ved fremstilling af et medikament til behandling af iskæmisk hjerneödelæggelse og demens |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5736515A (es) |
| EP (1) | EP0720483B1 (es) |
| JP (1) | JPH09502973A (es) |
| AT (1) | ATE263573T1 (es) |
| AU (1) | AU683306B2 (es) |
| CA (1) | CA2168570C (es) |
| DE (1) | DE69433687T2 (es) |
| DK (1) | DK0720483T3 (es) |
| ES (1) | ES2218529T3 (es) |
| NZ (1) | NZ274025A (es) |
| PT (1) | PT720483E (es) |
| SE (1) | SE9303068D0 (es) |
| WO (1) | WO1995008345A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
| US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
| EP1109572A4 (en) | 1998-09-03 | 2004-11-24 | Neuronz Ltd | NEUROPROTECTION |
| EP1149583A3 (en) * | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
| BR0318426A (pt) * | 2003-07-29 | 2006-08-01 | Ares Trading Sa | uso de hormÈnio de crescimento humano em atrofia multissistêmica |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2974088A (en) * | 1958-07-18 | 1961-03-07 | Merck & Co Inc | Method of preparing growth hormone |
| US3118815A (en) * | 1959-09-28 | 1964-01-21 | Upjohn Co | Growth hormone and recovery thereof |
| EP0103395A3 (en) * | 1982-08-17 | 1985-05-22 | Biogen N.V. | Dna sequences, recombinant dna molecules and processes for producing bovine growth hormone-like polypeptides in high yield |
| US4521409A (en) * | 1983-10-03 | 1985-06-04 | Cornell Research Foundation, Inc. | Use of growth hormone to enhance ruminant mammary development |
| WO1986004308A1 (en) * | 1985-01-28 | 1986-07-31 | Seung Moon Park | Lighting apparatus for wheels of vehicles |
| US4670249A (en) * | 1985-04-12 | 1987-06-02 | International Minerals & Chemical Corp. | Growth-promoting compositions |
| US4786501A (en) * | 1985-07-15 | 1988-11-22 | International Minerals & Chemical Corp. | Cylindrical implants for the controlled release of growth hormones |
| IL79681A (en) * | 1985-08-12 | 1991-06-10 | Int Minerals & Chem Corp | Transition metal complexes of growth hormones and their prolonged release compositions |
| US4977140A (en) * | 1985-08-23 | 1990-12-11 | Eli Lilly And Company | Injectable sustained release formulation |
| CA1285874C (en) * | 1985-08-23 | 1991-07-09 | Thomas Harry Ferguson | Injectable sustained release formulation |
| US4857506A (en) * | 1987-01-12 | 1989-08-15 | American Cyanamid Company | Sustained release growth hormone compositions for parenteral administration and their use |
| US4863736A (en) * | 1987-03-16 | 1989-09-05 | Monsanto Company | Somatotropin prolonged release |
| NZ223842A (en) * | 1988-03-10 | 1991-07-26 | Amgen Inc | Porcine growth hormone analogues, production using genetic engineering and compositions for promoting growth in mammals |
-
1993
- 1993-09-21 SE SE9303068A patent/SE9303068D0/xx unknown
-
1994
- 1994-09-21 PT PT94928538T patent/PT720483E/pt unknown
- 1994-09-21 JP JP7509721A patent/JPH09502973A/ja active Pending
- 1994-09-21 CA CA002168570A patent/CA2168570C/en not_active Expired - Fee Related
- 1994-09-21 WO PCT/SE1994/000875 patent/WO1995008345A1/en active IP Right Grant
- 1994-09-21 AU AU77933/94A patent/AU683306B2/en not_active Ceased
- 1994-09-21 DK DK94928538T patent/DK0720483T3/da active
- 1994-09-21 EP EP94928538A patent/EP0720483B1/en not_active Expired - Lifetime
- 1994-09-21 DE DE69433687T patent/DE69433687T2/de not_active Expired - Lifetime
- 1994-09-21 US US08/602,728 patent/US5736515A/en not_active Expired - Lifetime
- 1994-09-21 ES ES94928538T patent/ES2218529T3/es not_active Expired - Lifetime
- 1994-09-21 AT AT94928538T patent/ATE263573T1/de active
- 1994-09-21 NZ NZ274025A patent/NZ274025A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2218529T3 (es) | 2004-11-16 |
| DE69433687D1 (de) | 2004-05-13 |
| CA2168570A1 (en) | 1995-03-30 |
| WO1995008345A1 (en) | 1995-03-30 |
| DE69433687T2 (de) | 2005-03-17 |
| CA2168570C (en) | 2009-04-07 |
| AU7793394A (en) | 1995-04-10 |
| EP0720483A1 (en) | 1996-07-10 |
| PT720483E (pt) | 2004-08-31 |
| NZ274025A (en) | 2005-03-24 |
| ATE263573T1 (de) | 2004-04-15 |
| US5736515A (en) | 1998-04-07 |
| EP0720483B1 (en) | 2004-04-07 |
| JPH09502973A (ja) | 1997-03-25 |
| SE9303068D0 (sv) | 1993-09-21 |
| AU683306B2 (en) | 1997-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0659083T3 (da) | Forebyggelse og behandling af perifer neuropati | |
| SG52365A1 (en) | New pharmaceutical formulation | |
| SE9604793L (sv) | Nya Kristallmodifikationer | |
| EP0476044A4 (en) | Treating disorders by application of insulin-like growth factors and analogs | |
| DE69819748D1 (de) | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen | |
| ATE185548T1 (de) | Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress | |
| DE69332310T2 (de) | Verfahren zur herstellung von vorgefüllten, sterilen abgabevorrichtungen. | |
| ATE207352T1 (de) | Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen | |
| DK0436469T3 (da) | Præparat og fremgangsmåde til behandling af osteoporose i pattedyr | |
| PL320167A1 (en) | 2,2-dichloroalkanocarboxylic acids, method of obtaining them and therapeutic agents containing such compounds and their application in treating insulin immunity | |
| DE69316013D1 (de) | Verwendung von phosphinate zur behandlung der osteoporose | |
| DK0720483T3 (da) | Anvendelse af væksthormon ved fremstilling af et medikament til behandling af iskæmisk hjerneödelæggelse og demens | |
| CA2074166A1 (en) | Method for treating intestinal diseases | |
| DE69301750D1 (de) | Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose | |
| ATE157010T1 (de) | Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen | |
| DE69332541D1 (de) | Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie | |
| DE69023006D1 (de) | Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen. | |
| DE69026087D1 (de) | Substituierte 2-imidazoline und verfahren zur herstellung sowie deren verwendung | |
| NO911237L (no) | Fremgangsmaate for fremstilling av hydroxymethyl-indolizidiner og kinolizidiner | |
| DE69627379D1 (de) | Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem | |
| DK0538897T3 (da) | Anvendelse af BMY 14802 ved behandling af angst hos benzodiazepinseponerede patienter | |
| SE9501773D0 (sv) | New use | |
| ATE44751T1 (de) | Zusammensetzungen zum behandeln von ischaemie im gehirn. |